USPTO Patent Grant US12583892B2: Conus Peptides for Neurodegenerative Conditions

ChangeBridge: Patent Grants - Peptides (C07K)

Published March 24th, 2026

Detected March 24th, 2026

Summary

The USPTO has granted patent US12583892B2 to Technion Research and Development Foundation Limited for modified Conantokin peptides and their use in treating neurodegenerative conditions. The patent covers specific peptide forms, nucleic acids encoding them, and compositions for modulating NMDA receptors.

View original document View source feed page

What changed

USPTO patent grant US12583892B2 has been issued to Technion Research and Development Foundation Limited. The patent covers modified Conantokin peptides, nucleic acids encoding these peptides, and their application in treating neurodegenerative conditions by modulating NMDA receptors. The abstract details the invention, including chimeric polypeptides and their expression on target cell membranes.

This patent grant is a notification of intellectual property protection for a specific invention. It does not impose new regulatory obligations on regulated entities. Companies involved in pharmaceutical research and development, particularly in the areas of neurodegenerative diseases and peptide therapeutics, may find this patent relevant for competitive intelligence and freedom-to-operate analysis.

Source document (simplified)

← USPTO Patent Grants

Conus-based toxin peptides, nucleic acids encoding same and uses thereof in modulating NMDA receptors

Grant US12583892B2 Kind: B2 Mar 24, 2026

Assignee

TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LIMITED

Inventors

Shai Berlin, Ido Carmi, Shaden Zoabi

Abstract

Provided herein are modified forms of Conantokin peptides, including, modified Con-P peptides, nucleic acids encoding the same and compositions thereof. Further provided are nucleic acid molecules encoding for chimeric modified conantokin polypeptides to be expressed in or on a membrane of a target cells, compositions comprising the same and uses thereof for treating various neurodegenerative conditions.